Direct answer: No universal chart converts compounded tirzepatide into syringe units. The Zepbound and Mounjaro labels describe doses in milligrams and use standardized presentations. Compounded products vary in concentration, container, device, and directions, so only the patient-specific label and the dispensing pharmacist can say what volume a prescribed milligram amount represents.
Critical distinction: The table below summarizes the 2026 FDA-approved Zepbound label. It establishes no equivalence, potency, or unit conversion for any compounded product.
Current Zepbound label reference
| Stage | FDA-labeled dosage | Label purpose |
|---|---|---|
| Initiation | 2.5 mg once weekly for 4 weeks | Initiation only, not an approved maintenance dosage |
| First increase | 5 mg once weekly | Reached after the initiation period |
| Later increases | 2.5 mg increments after at least 4 weeks on the current dosage | Selected according to response and tolerability |
| Weight reduction maintenance | 5 mg, 10 mg, or 15 mg once weekly | Recommended maintenance options for the labeled weight indication |
| Obstructive sleep apnea maintenance | 10 mg or 15 mg once weekly | Recommended maintenance options for the labeled OSA indication |
| Maximum | 15 mg once weekly | Maximum labeled dosage |
The Mounjaro label covers glycemic control in type 2 diabetes for adults and patients aged 10 and older, and should be read separately. A prescriber may decide not to increase simply because a minimum interval has passed.
Why this is not a compounded-product conversion chart
A milligram is a mass of drug and a milliliter is a volume. A syringe “unit” is a device marking that represents a volume on that device. Concentration is what connects the two, so without it a unit count has no fixed tirzepatide meaning.
Compounded products may differ by concentration, total volume, dosage form, container, preservatives, added ingredients, and dispensing directions. Even products from the same pharmacy can change. Never reuse a previous unit count after a refill, concentration change, new pharmacy, or new device.
Telehealth programs that dispense compounded tirzepatide, among them Ro, Hims and Hers, and formblends.com, work through licensed compounding pharmacies, so the dispensed concentration should be identifiable from the order record as well as the vial. That makes a change between refills easier to notice, but it does not make the product FDA-approved.
Approved tirzepatide and compounded products are not interchangeable categories
Zepbound and Mounjaro are FDA-approved products with reviewed manufacturing, labeling, clinical evidence, and quality controls. Compounded drugs are not FDA approved and get no comparable premarket review.
FDA has warned telehealth companies against implying compounded GLP-1 products are generic or clinically equivalent to approved drugs. A brand schedule gives clinical context but cannot validate the identity, concentration, sterility, or directions of a compounded vial.
Current U.S. compounding context
FDA declared the tirzepatide injection shortage resolved in October 2024. FDA’s April 2026 update states that tirzepatide does not appear on the 503B Bulks List or the drug shortage list. Federal law also restricts compounding products that are essentially copies of commercially available approved drugs.
On April 30, 2026, FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances. A proposal is not the same as a final determination, but it is material current context. A patient-specific medical need and applicable law require professional review.
Because concentration lives on the label rather than in a marketing name, it is worth checking how each provider presents its product. Clinics that prescribe tirzepatide, including Henry Meds, LillyDirect, and HealthRX, describe their tirzepatide options at the program level, which is a place to begin questions but never a substitute for the dispensed vial’s own label.
The patient-specific label check
| Check | What must be explicit | Stop condition |
|---|---|---|
| Patient and prescription | Correct name, prescriber, and current directions | Label belongs to another person or an old prescription |
| Active ingredient | Tirzepatide and any additional ingredient | Marketing name substitutes for ingredient identity |
| Concentration | Milligrams per milliliter or an unambiguous equivalent | Only total milligrams or only “units” appear |
| Prescribed amount | Milligrams plus corresponding product-specific volume | Directions require independent online math |
| Device | Device type and markings match directions | Device differs from the pharmacy instruction |
| Product lifecycle | Lot, storage, beyond-use date, and dispenser contact | Missing traceability, expired product, or storage failure |
If any field is missing or contradictory, do not administer. Ask the prescriber and pharmacist to reconcile the directions in writing.
How starting decisions are made
The approved label supplies a starting schedule, but prescribing still requires confirming the indication, contraindications, other glucose-lowering medicines, pregnancy plans, gastrointestinal and kidney risk, planned sedation, and whether the person can use the supplied presentation.
Escalation depends on more than the calendar
The label permits later increases only after at least four weeks on the current dosage. “At least” is not the same as an automatic increase every four weeks. Response, gastrointestinal symptoms, hydration, glycemic control, and the treatment goal all matter.
Do not increase for a single week of scale fluctuation, end-of-week hunger, social-media expectations, or because medication remains in a vial.
What “maintenance dosage” actually means
The Zepbound label lists more than one maintenance option. The appropriate maintenance dosage depends on indication, response, and tolerability. Intermediate escalation steps are not automatically long-term targets, and reaching the highest dose is not required for treatment to be successful.
Missed or delayed dose
The Zepbound and Mounjaro labels state that a missed dose may be administered as soon as possible within four days. If more than four days have passed, skip it and take the next dose on the regular day. Do not take two doses within three days of each other.
Those label rules do not resolve an unclear compounded label, multiple missed doses, significant side effects, or a concentration change, all of which need the prescriber or pharmacist.
Why dosing errors happen
- Confusing milligrams, milliliters, and syringe units
- Using a chart for a different concentration or an old refill
- Reading total vial content as a single dose
- Using the wrong syringe, or moving a decimal
- Self-reconstituting research powder
FDA reports dosing errors involving compounded semaglutide and tirzepatide, including errors by patients and health professionals and compounded doses beyond approved labeling. A calculator cannot replace a verified label.
If too much may have been administered
Do not take another dose or try to counteract the error. Record the product, concentration as labeled, estimated volume, device, time, symptoms, and other medicines. Contact the prescriber, dispensing pharmacist, or Poison Control at 1-800-222-1222. Call emergency services for severe symptoms, fainting, confusion, trouble breathing, or inability to remain hydrated.
The approved labels note that observation may need to account for tirzepatide’s roughly five-day half-life, so feeling well immediately does not rule out later symptoms.
Monitoring and red flags
Common adverse reactions in approved-product trials are mainly gastrointestinal. Monitoring should also consider hydration, kidney function during volume depletion, glucose when insulin or a sulfonylurea is used, gallbladder and pancreatitis symptoms, and planned anesthesia or deep sedation.
Seek prompt care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, very low blood sugar symptoms, reduced urination, facial or throat swelling, trouble breathing, fainting, or a serious injection-site infection.
Storage belongs to the exact product
Approved Zepbound and Mounjaro storage instructions belong to their specific presentations. A compounded vial’s storage and beyond-use date must come from its dispensing pharmacy. Do not transfer a brand product’s room-temperature window to a compounded one.
Do not use a product after an unexplained temperature excursion, broken seal, label loss, visible particles, or leakage until the dispenser evaluates it.
The three-party verification rule
- Prescriber: confirms the indication, milligram dose, schedule, monitoring, and change plan.
- Dispensing pharmacist: confirms the exact product concentration, volume, device, label, storage, and administration instructions.
- Patient: compares the container and written instructions before each use and stops when anything differs.
An online chart is not a fourth authority. It cannot see the prescription or test the vial.
Frequently asked questions
Can the same number of syringe units be used after a refill?
Not unless the pharmacist confirms the concentration, device, and directions are unchanged.
Is compounded tirzepatide a generic Zepbound or Mounjaro?
No. FDA has warned against claims that unapproved compounded GLP-1 products are generic, the same as, or clinically proven equivalent to approved drugs.
Can someone round to the nearest syringe marking?
Do not independently round. If the prescribed volume cannot be measured clearly with the supplied device, the pharmacy must correct the device, concentration, or directions.
Can excess drawn medication be pushed back into a vial?
No. That risks contamination and measurement error. Follow the pharmacy instructions for the exact product.
